K993024

MAR 1 3 2000

II 510(k) Summary of Safety and Effectiveness in Accordance with SMDA'90

B. Braun Medical, Inc
901 Marcon Boulevard
Allentown, PA 18103
(610)266-0500 ext. 2261

September 7, 1999

Contact: Mark S. Alsberge, Regulatory Affairs Director

Product Name: Celsite® Implantable Port with Valved Catheter

Trade Name: **Catheter, Intravascular, Long Term**

Classification name: Unclassified, LJT

SUBSTANTIAL EQUIVALENCE[1] TO:

510(k) number	Name	Applicant
K952548	Celsite Venous Access System	B. Braun Medical, Inc.

Device Description:

In accordance with section 510(k) for the Federal Food, Drug, and Cosmetic Act, B. Braun Medical, Inc. intends to introduce into interstate commerce the Celsite® Implantable Port with Valved Catheter which is used intravenously over a long period of time for the administration of drugs for chemotherapy, anti-biotics, anti-viral drugs, and for parenteral nutrition. They are also used for blood transfusions or blood sampling in small quantities.

---

[1] The term "substantially equivalent" as use herein is intended to be a determination of substantial equivalence from an FDA -regulatory point of view under the Federal Food, Drug, and Cosmetic Act and relates to the fact that the product can be marketed without premarket approval or reclassification. These products may be considered distinct from a patent point of view. The term "substantially equivalent" is not applicable to and does not diminish any patent claims related to this product or the technology used to manufacture the product.

Material:

The Celsite® Implantable Port with Valved Catheter is composed of materials that have been tested in accordance with the ISO Standard 10993-1 and have been determined to be suitable for the intended use of this product.

Substantial equivalence:

The Celsite® Implantable Port with Valved Catheter is similar in materials, form and intended use to the Celsite® Venous Access System, K952548 cleared by B. Braun Medical Inc. formally known as Burron Medical. We have not made any modifications to the port or the port connector. This submission is to introduce a new valved catheter that may be offered as an option to the predicate catheter in K952548. There are no new issues of safety or effectiveness raised by the Celsite® Implantable Port with Valved Catheter.

Safety And Effectiveness:

All finished products are tested and must meet all required release specifications before distribution. The array of testing required for release include, but are not limited to; physical testing, visual examination (in process and finished product).

The physical testing is defined by Quality Control Test Procedure documents. These tests are established testing procedures and parameters which conform to the product design specifications.

The testing instruction records for each of the individually required procedures are approved, released, distributed and revised in accordance with document control cGMP"s.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

MAR 13 2000

Mr. Mark S. Alsberge
Regulatory Affairs Director
B. Braun Medical, Inc.
901 Marcon Boulevard
Allentown, Pennsylvania 18103

Re: K993024
Trade Name: Celsite® Implantable Port with Valved Catheter
Regulatory Class: Unclassified
Product Code: LJT
Dated: January 26, 2000
Received: January 27, 2000

Dear Mr. Alsberge:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of

the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4690. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Timothy A. Ulatowski
Director
Division of Dental, Infection Control,
and General Hospital Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K993024

Device Name: Celsite Implantable Port with Valved Catheter

Indications For Use:

Used intravenously over a long period of time for the administration of drugs for chemotherapy, anti-biotics, anti-viral drugs, and for parenteral nutrition. They are also used for blood transfusions or blood sampling in small quantities.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Vicki Hilliard for Pat Cucenti

(Division Sign-Off)
Division of Dental, Infection Control,
and General Hospital Devices
510(k) Number K993024

Prescription Use X OR Over-The-Counter Use _____
(Per 21 CFR 801.109)

(Optional Format 1-2-96)